

DAFTAR PUSTAKA

1. ACS. What Is Lung Cancer? | Types of Lung Cancer. American Cancer Society. 2019.
2. Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. *Front Oncol.* 2017;7(AUG):1–7.
3. Dela Cruz CS, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology, and Prevention. *Clin Chest Med.* 2011;32(4):605–44.
4. Fatmawati F. Kanker Paru. *Kanker Paru.* 2019;125–43.
5. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. *Transl Lung Cancer Res.* 2018;7(3):220–33.
6. World Health Organization. Indonesia Source GLOBOCAN 2018. *Int Agency Res Cancer.* 2019;256:1–2.
7. dr. Achmad Hudoyo S, dkk. Panduan Pelaksanaan Kanker paru. 2016;33.
8. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-Small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). *Am J Cancer Res.* 2015;5(9):2892–911.
9. Kemenkes RI. Artikel Hari Kanker Sedunia 2019. Kemenkes RI. 2019;
10. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin.* 2016;66(1):7–30.
11. El-Telbany A, Ma PC. Cancer Genes in Lung Cancer: Racial Disparities: Are There Any? Vol. 3, *Genes and Cancer.* 2012. p. 467–80.
12. Shi Y, Li J, Zhang S, Wang M, Yang S, Li N, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - Mainland China subset analysis of the PIONEER study. *PLoS One.* 2015;10(11):1–10.
13. My Cancer Genome. EGFR Mutation - My Cancer Genome. 2017.
14. Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. *Cancers (Basel).* 2017;9(5):1–45.
15. Liu TC, Jin X, Wang Y, Wang K. Role of epidermal growth factor receptor in lung cancer and targeted therapies. *Am J Cancer Res.* 2017;7(2):187–202.

16. SARI L, PURWANTO P. Mutasi EGFR pada Non-Small Cell Lung Cancer di Rumah Sakit Kanker “Dharmais.” *Indones J Cancer*. 2017;10(4):131.
17. Utara US, Utara US, Utara US. Proporsi Mutasi Gen Epidermal Growth Factor Receptor (EGFR) dari Tissue Biopsy dan Liquid Biopsy ctDNA pada KPKBSK Jenis Adenokarsinoma di. 2019;
18. Guo L, Chen Z, Xu C, Zhang X, Yan H, Su J, et al. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. *BMC Cancer*. 2019;19(1):1–8.
19. Roche Molecular Systems I. Cobas EGFR - Manual. cobas® EGFR Mutat Test. 2015;
20. Sculier JP, Berghmans T, Meert AP. Advances in target therapy in lung cancer. *Eur Respir Rev*. 2015;24(135):23–9.
21. Dong J, Li B, Lin D, Zhou Q, Huang D. Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing. *Front Pharmacol*. 2019;10(March):1–10.
22. Gaur P, Bhattacharya S, Kant S, Kushwaha RAS, Singh G, Pandey S. EGFR Mutation Detection and Its Association With Clinicopathological Characters of Lung Cancer Patients. *World J Oncol*. 2018;9(5–6):151–5.
23. Zaini J, Syahrudin E, Yunus M, Andarini SL, Hudoyo A, Masykura N, et al. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients. *Cancer Rep*. 2019;2(4):1–9.
24. Michal Skronski, Tomoaki Tanaka, Adam Szpehcinski, Renata Langfort, Tadeusz Orłowski, Koichi Hagiwara JC-W. Evaluation of highly sensitive PNA-LNA PCR clamp method for EGFR L858R mutation detection in lung adenocarcinoma patients. *European Respiratory Journal*. 2011.
25. Chrzanowska NM, Kowalewski J, Lewandowska MA. Use of fluorescence in situ hybridization (FISH) in diagnosis and tailored therapies in solid tumors. *Molecules*. 2020;25(8):1–21.
26. Yoon SH, Choi YD, Oh IJ, Kim KS, Choi H, Chang J, et al. Peptide nucleic acid clamping versus direct sequencing for the detection of EGFR gene mutation in patients with non-small cell lung cancer. *Cancer Res Treat*. 2015;47(4):661–9.
27. Popovska SL, Dineva TB, Damyanova PD. © Medical University Pleven © Medical University Pleven. 2018;10(2):5–10.
28. Fenizia F, De Luca A, Pasquale R, Sacco A, Forgione L, Lambiase M, et

- al. EGFR mutations in lung cancer: From tissue testing to liquid biopsy. *Futur Oncol.* 2015;11(11):1611–23.
29. Ilić M, Hofman P. Pros : Can tissue biopsy be replaced by liquid biopsy? 2016;5(4):420–3.
 30. Project HG. Tissue Collection for Molecular Genetic Analysis. In 2003. p. 0–1.
 31. What Is FFPE Tissue And What Are Its Uses - BioChain Institute Inc.
 32. Raffaele Palmirotta , Domenica Lovero, Paola Cafforio CF, Francesco Mannavola, Eleonora Pellè, Davide Quaresmini MT, Silvestris and F. Liquid biopsy of cancer a multimodal diagnostic tool in clinical oncology. *Liq biopsy cancer a multimodal diagnostic tool Clin Oncol.* 2018;10.
 33. Sahoo T. Liquid biopsy in oncology practice. *Oncol J India.* 2018;2(3):45.
 34. Liquid Biopsy_ Revolutionizing Cancer Diagnoses and Treatments - BioChain Institute Inc.
 35. Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. *Oncotarget.* 2017;8(7):12501–16.
 36. Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? *Ann Transl Med.* 2017;5(3):1–7.
 37. Paulsen F, Waschke J. Viscera of the thorax. *Sobotta atlas Hum Anat Intern organs.* 2011;4–62.
 38. Warwick R, Williams PL, Dyson M, Bannister L. “Gray’s Anatomy.” *Br J Radiol.* 1985;58(694):1029–1029.
 39. Costanzo LS, Blvd JFK. FIFTH EDITION Linda S. Costanzo, PhD. 2014.
 40. Eroschenko VP. *Atlas Histologi, diFiore. EGC.* 2011. 505 p.
 41. Mescher A. *Junqueras’s Basic Histology Text and Atlas.* 2016. 423–425 p.
 42. Putriani FA, Kholis FN, Purwoko Y. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru Dengan Mutasi Egfr Dan Non Mutasi Egfr. *Diponegoro Med J (Jurnal Kedokt Diponegoro).* 2019;8(1):214–21.
 43. Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. *Eur Respir J.* 2016;48(3):889–902.
 44. Cassidy, Jim. Bissett, Donald. Spence, Roy. Payne M. *Oxford Handbook od Oncology.* 2010. 38 p.

45. Patricia de Groot, MD*, Reginald F. Munden, MD, DMD M. Lung Cancer Epidemiology, Risk Factors, and Prevention. 2017;
46. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. *J Thorac Dis.* 2010;2(1):48–51.
47. Cheng L, Alexander RE, MacLennan GT, Cummings OW, Montironi R, Lopez-Beltran A, et al. Molecular pathology of lung cancer: Key to personalized medicine. *Mod Pathol.* 2012;25(3):347–69.
48. Jameson, Fauci K. *Harrison's Principles Of Internal Medicine.*
49. Lim W, Ridge CA, Nicholson AG, Mirsadraee S. The 8th lung cancer TNM classification and clinical staging system: Review of the changes and clinical implications. *Quant Imaging Med Surg.* 2018;8(7):709–18.
50. Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD P. *Small Cell Lung Cancer (SCLC)_ Practice Essentials, Pathophysiology, Etiology.* 2020.
51. Tan W. *Non-Small Cell Lung Cancer (NSCLC): Practice Essentials, Background, Pathophysiology.* Medscape. 2019.
52. Pal P, Tsao M, Adenocar- P. *Pulmonary Adenocarcinoma — Pathology and Molecular Testing Non – Small Cell Carcinomas of the Lung Hierarchical k-Means.* 2019;
53. Li X, Zhou C. Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. *Oncotarget.* 2017;8(59):100801–18.
54. Travis, William D, Brambilla E, Burke AP, Marx A NA. *WHO classification of tumours of the lung, pleura, thymus and heart.* 2015;
55. Nguyen GK SB. *Atlas and Textbook lung cytology.* 2014.
56. Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD P. *Small Cell Lung Cancer (SCLC).* 2020.
57. *Non-Small Cell Lung Cancer Treatment (PDQ®)—Patient Version - National Cancer Institute.* 2019.
58. Pelosi G, Barbareschi M, Cavazza A, Graziano P, Rossi G, Papotti M. Large cell carcinoma of the lung: A tumor in search of an author. A clinically oriented critical reappraisal. *Lung Cancer.* 2015;87(3):226–31.
59. International Association for the Study of Lung Cancer. *Staging Handbook In Thoracic Oncology.* 2016. 188 p.

60. American Cancer Society. Non-small Cell Lung Cancer Staging | Stages of Lung Cancer. 2019.
61. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors guideline from the college of American pathologists, the international association for the study of lung cancer, and the a. Arch Pathol Lab Med. 2018;142(3):321–46.
62. Kadara H, Scheet P, Wistuba II, Spira AE. Early events in the molecular pathogenesis of lung cancer. Cancer Prev Res. 2016;9(7):518–27.
63. Yoshida T, Zhang G HE. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. 2010;
64. Latimer KM, Mott TF, Pensacola NH. Lung Cancer: Diagnosis, Treatment Principles, and Screening. 2015;
65. Araujo LH, Horn L, Merritt RE, Shilo K, Xu-Welliver M CD. Cancer of the Lung: Non-small cell lung cancer and small cell lung cancer in neiderhuber. 2019.
66. Ferraro P, Liberman M. Diagnostic Accuracy of Mediastinal Lymph Node Staging. 2018;25(1):17–24.
67. Ling B, Liao X, Huang Y, Liang L, Jiang Y, Pang Y, et al. Identification of prognostic markers of lung cancer through bioinformatics analysis and in vitro experiments. Int J Oncol. 2020;56(1):193–205.
68. Satrianawaty LD, Sumarno TM, Prabowo S. Hang tuah medical journal. Hang Tuah Med J. 2019;17(1):35–46.
69. Wass RE, Lang D, Lamprecht B, Studnicka M. Targeted therapy in lung cancer—ASCO 2019 update. Memo - Mag Eur Med Oncol. 2019;12(4):301–4.
70. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167–79.
71. SPECIMEN REQUIREMENTS - MOLECULAR GENETICS.
72. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: Standardization for use in the clinical trial setting. J Clin Oncol. 2008;26(6):983–94.
73. Glick BR, Pasternak JJ, Patten CL. Molecular Biotechnology Principles and Application of Recombinant DNA. In: 4th ed. ASM Press; 2010.

74. Direct Sequencing Of DNA, RNA Using Novel Technique -- ScienceDaily.
75. Khan Academy. DNA sequencing (article) | Biotechnology | Khan Academy. Khan Academy. 2018.
76. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. From DNA to RNA - Molecular Biology of the Cell - NCBI Bookshelf. 2002.
77. Bader AS, Hawley BR, Wilczynska A, Bushell M. The roles of RNA in DNA double-strand break repair. *Br J Cancer*. 2020;122(5):613–23.
78. Obradovic J, Jurisic V. Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients. *Multidiscip Respir Med*. 2012;7(7):1.
79. Feng Q, Yang Z, Zhang J, Tang J. Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis. 2017;8(35):59552–62.
80. Kawada I, Soejima K, Watanabe H, Nakachi I, Yasuda H, Naoki K, et al. An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. *J Thorac Oncol*. 2008;3(10):1096–103.
81. Min KW, Kim WS, Jang SJ, Choi YD, Chang S, Jung SH, et al. Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study. *Qjm*. 2016;109(3):167–73.
82. Mahdieh N, Rabbani B. An overview of mutation detection methods in genetic disorders. *Iran J Pediatr*. 2013;23(4):375–88.
83. Mittal B, Chaturvedi P, Tulsyan S. Restriction Fragment Length Polymorphism. *Brenner's Encycl Genet Second Ed*. 2013;190–3.
84. Dai S, Long Y. Chapter 7 Genotyping Analysis Using an RFLP Assay. *Plant Genotyping Methods Protoc*. 2015;1245:91–9.
85. Budiarto BR. Kaitan genotyping errors dengan performa diagnostik molekuler kanker berbasis amplifikasi asam nukleat. *Biodidaktika, J Biol Dan Pembelajarannya*. 2018;13(2):1–18.
86. ThermoFisher Scientific. Real-Time PCR Hand-Book. 2012;11(1):85–95.
87. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B, et al. Real-time PCR handbook. *Life Journals*. 2015;4(2):189–200.
88. Real Time Thermal Cycler.

89. Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, et al. EGFR fluorescence in situ hybridisation assay: Guidelines for application to non-small-cell lung cancer. *J Clin Pathol*. 2009;62(11):970–7.
90. Bylicki O, Paleiron N, Assié JB, Chouaïd C. Targeting the met-signaling pathway in non-small-cell lung cancer: Evidence to date. *Onco Targets Ther*. 2020;13:5691–706.
91. michael W. Pfaffi jo vandesompele mikael. Real-Time PCR; current technology and applications. *Asp Gen La Planif Tribut En Venez*. 2009;2009(75):31–47.
92. Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, et al. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. *Futur Oncol*. 2011;7(4):519–41.
93. Onozato ML, Yapp C, Richardson D, Sundaresan T, Chahal V, Lee J, et al. Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics. *J Mol Diagnostics*. 2019;21(3):390–407.
94. Fluorescence in Situ Hybridization (FISH) - Cytogenetics Core - Mayo Clinic Research. Mayo Clinic.
95. Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, et al. EGFR fluorescence in situ hybridisation assay: Guidelines for application to non-small-cell lung cancer. *J Clin Pathol*. 2009;62(11):970–7.
96. de Groot P, Munden RF. Lung Cancer Epidemiology, Risk Factors, and Prevention. *Radiol Clin North Am*. 2012;50(5):863–76.
97. Bachman J. Reverse-transcription PCR (RT-PCR). 1st ed. Vol. 530, *Methods in Enzymology*. Elsevier Inc.; 2013. 67–74 p.